NCT04246177 2026-04-22
LEAP-012
Merck Sharp & Dohme LLC
Phase 3 Completed
Clinical Trials
23 trialsNCT07537946 2026-04-17
Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer
Tongji Hospital
Phase 3 Not yet recruiting
NCT03778957 2026-04-15
EMERALD-1
AstraZeneca
Phase 3 Active not recruiting
NCT02771405 2026-04-13
FRI-STC
National Hepatology & Tropical Medicine Research Institute
Phase 3 Completed
NCT07166406 2026-04-08
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
NRG Oncology
Phase 3 Recruiting
NCT05301842 2026-04-07
EMERALD-3
AstraZeneca
Phase 3 Active not recruiting
NCT04039607 2026-04-06
CheckMate 9DW
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT00116454 2026-04-03
Lipiocis
ANRS, Emerging Infectious Diseases
Phase 3 Completed
NCT03186898 2026-04-03
Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer
NRG Oncology
Phase 3 Active not recruiting
NCT02435953 2026-03-31
TORCH
Sun Yat-sen University
Phase 3 Completed
NCT03298451 2026-03-20
HIMALAYA
AstraZeneca
Phase 3 Active not recruiting
NCT04102098 2026-03-19
IMbrave050
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT04720716 2026-03-19
A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT07475026 2026-03-16
A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Not yet recruiting
NCT07461675 2026-03-10
Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection
University of Geneva, Switzerland
Phase 3 Not yet recruiting
NCT04777851 2026-03-09
REPLACE
Translational Research in Oncology
Phase 3 Terminated
NCT03847428 2026-03-06
EMERALD-2
AstraZeneca
Phase 3 Active not recruiting
NCT07417397 2026-02-18
Adjuvant TACE in HCC With High-risk Recurrence Factors
Guangxi Medical University
Phase 3 Recruiting
NCT03713593 2026-02-05
LEAP-002
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03867084 2026-02-04
KEYNOTE-937
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT07381660 2026-02-02
SBRT Versus Surgical Resection for Small HCC
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT04712643 2026-01-30
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT01730937 2026-01-28
Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
Radiation Therapy Oncology Group
Phase 3 Completed